Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 15Pemetrexed 12pembrolizumab 9Carboplatin 8Nivolumab 7Cyclophosphamide 6Platinum 5Ipilimumab 51,2-diaminocyclohexaneplatinum II citrate 5fludarabine 3Radiotherapy, Intensity-Modulated 3Interleukin-2 3Gemcitabine 3tremelimumab 2durvalumab 2atezolizumab 2aldesleukin 2Radiotherapy 2Radiation 2Photochemotherapy 2Pharmaceutical Preparations 2Methotrexate 2Drug Therapy 2Chemotherapy, Adjuvant 2Cerebral Decortication 2nintedanib 1methoxyamine 1decitabine and cedazuridine drug combination 1cemiplimab 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × methoxyamine × 1 year × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡